Form4insider filings, from the source

SEC Form 4 · accession 0001214659-26-011121

Alzamend Neuro, Inc. · ALZN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Period of report
Aug 26, 2026
Accepted (ET)
Aug 31, 2026 · 6:05 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001677077

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2Aug 26, 2026S2,000$1.5581D0D
Common StockF3holding———116,648IBy Ault Lending, LLC
Common StockF4holding———11,068IBy Ault Life Sciences, Inc.
Common StockF5holding———61IBy Ault Life Sciences Fund, LLC

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

Mr. Ault, the Executive Chairman of HSD, which wholly owns ACG, which in turn wholly owns Ault Lending, is a director of the Issuer. For purposes of Section 16 of the Exchange Act, each of HSD, ACG and Ault Lending may be deemed a director by deputization by virtue of their respective representation on the Board of Directors of the Issuer.